• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA expands Myoview label

Article

Amersham Health has won FDA approval to market its Myoview radiopharmaceutical for the assessment of left ventricular function, specifically the calculation of LV ejection fraction and wall motion, in patients being evaluated for heart disease. The

Amersham Health has won FDA approval to market its Myoview radiopharmaceutical for the assessment of left ventricular function, specifically the calculation of LV ejection fraction and wall motion, in patients being evaluated for heart disease. The company's second largest selling product was first FDA approved and introduced in the U.S. in 1996 for cardiac perfusion studies. The additional indication is the latest example of Amersham's corporate strategy to expand the clinical utility of current products (SCAN 4/17/02).

In 2001, the FDA expanded Myoview labeling to include its use with pharmacologic stress agents in patients with known or suspected coronary artery disease. Last year, European authorities approved its use for imaging breast cancer. The product currently accounts for about 40% of the technetium cardiac market and more than 30% of the global myocardial perfusion market, according to Amersham.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.